This article is more than 5 years old. Information may no longer be current.

First patient dosed in Innovent wet AMD trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Innovent Biologics has dosed the first patient in a phase 1 trial of IBI302, the company’s wet age-related macular degeneration treatment candidate, according to a press release.

A single intravitreal injection of IBI302, a recombinant fully human bispecific fusion protein targeting VEGF and complement proteins, will be evaluated in 36 patients with wet AMD in the open-label, single-center, dose escalation clinical trial.

“As the world’s first antibody-like bispecific fusion complement protein for ocular fundus diseases, IBI302 is designed to cure AMD by attacking its root causes in addition to relieving the symptoms,” Michael Yu, founder, CEO and chairman of Innovent, said in the release. “Hopefully, through our efforts, IBI302 can benefit AMD patients and their families.”